Of the 18 GnRH agonist-treated tumors, MED12 WT leiomyomas showed a higher shrinkage rate than MED12 MUT leiomyomas (44.1% vs. 15.6% reduction rate, p = 0.008, Mann–Whitney U test) (Table 1). This evidence concerns the gene GNRH1 and leiomyoma.